Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Bad Ischl

307 clinical trials in Bad Ischl, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Bad Ischl at a glance
307
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

307 trials in Bad Ischl

Open in trial search

Crohn's disease

Recruiting

Study of JNJ-78934804 (guselkumab and golimumab) versus guselkumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen - Cilag International

A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Cardiac failure

Recruiting

Study of maridebart cafraglutide for patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Long‑Term Safety and Efficacy of SPY001-001, SPY002 and SPY003 in Adults with Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ZL-1310
  • Sponsor:Zai Lab (US) LLC

Orelabrutinib in Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Orelabrutinib
  • Sponsor:Zenas Biopharma (USA) LLC

Crohn's disease

Recruiting

A study to evaluate the effectiveness and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Crohn's disease

Recruiting

A study to evaluate the efficacy and safety of duvakitug in patients with moderate to severe Crohn's disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A Study of Long-acting Antibodies SPY001-001 and SPY002 Alone and Combined for Adults with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:SPY001-001
  • Sponsor:Spyre Therapeutics Inc.

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.

A study of duvakitug for patients with moderately to severely active ulcerative colitis to see if it works and is safe as maintenance therapy

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

A study testing duvakitug for patients with moderately to severely active ulcerative colitis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Duvakitug
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Bad Ischl

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focused on Chronic Obstructive Pulmonary Disease (COPD) treatment optimization through combination therapy approaches. Studies explore the effectiveness of triple therapy combinations including bronchodilators and anti-inflammatory medications.

  • Triple Therapy Evaluation
  • Cardiopulmonary Outcomes
  • Treatment Optimization

Clinical investigations aim to improve patient outcomes in moderate to severe COPD cases.

02 Pulmonary Therapeutics

Advanced research examining the efficacy of benralizumab in treating patients with moderate to very severe COPD. Focus on reducing exacerbation frequency in patients with elevated blood eosinophils.

  • Exacerbation Management
  • Targeted Therapy
  • Disease Control

Studies specifically target patients with a history of frequent COPD exacerbations.

03 Respiratory Care Innovation

Development of new therapeutic approaches using metered-dose inhalers for COPD management. Research combines multiple active ingredients to achieve optimal bronchodilation and anti-inflammatory effects.

  • Medication Delivery Systems
  • Combination Therapies
  • Treatment Efficacy

Emphasis on improving delivery methods and treatment effectiveness for respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.